Division of Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2013 Dec;20(13):4282-8. doi: 10.1245/s10434-013-3212-2. Epub 2013 Aug 17.
Limited resection is an increasingly utilized option for treatment of clinical stage IA lung adenocarcinoma (ADC) ≤2 cm (T1aN0M0), yet there are no validated predictive factors for postoperative recurrence. We investigated the prognostic value of preoperative consolidation/tumor (C/T) ratio [on computed tomography (CT) scan] and maximum standardized uptake value (SUVmax) on (18)F-fluorodeoxyglucose-positron emission tomography (PET) scan.
We retrospectively reviewed 962 consecutive patients who underwent limited resection for lung cancer at Memorial Sloan-Kettering between 2000 and 2008. Patients with available CT and PET scans were included in the analysis. C/T ratio of 25 % (in accordance with the Japan Clinical Oncology Group 0201) and SUVmax of 2.2 (cohort median) were used as cutoffs. Cumulative incidence of recurrence (CIR) was assessed.
A total of 181 patients met the study inclusion criteria. Patients with a low C/T ratio (n = 15) had a significantly lower 5-year recurrence rate compared with patients with a high C/T ratio (n = 166) (5-year CIR, 0 vs. 33 %; p = 0.015), as did patients with low SUVmax (n = 86) compared with patients with high SUVmax (n = 95; 5-year CIR, 18 vs. 40 %; p = 0.002). Furthermore, within the high C/T ratio group, SUVmax further stratified risk of recurrence [5-year CIR, 22 % (low) vs. 40 % (high); p = 0.018].
With the expected increase in diagnoses of small lung ADC as a result of more widespread use of CT screening, C/T ratio and SUVmax are widely available markers that can be used to stratify the risk of recurrence among cT1aN0M0 patients after limited resection.
对于最大径≤2cm(T1aN0M0)的临床ⅠA 期肺腺癌(ADC),局限性切除术是一种应用日益广泛的治疗方法,但目前尚无术后复发的有效预测因素。我们研究了术前强化/肿瘤(C/T)比值(在 CT 扫描上)和最大标准化摄取值(SUVmax)在(18)F-氟代脱氧葡萄糖正电子发射断层扫描(PET)上的预后价值。
我们回顾性分析了 2000 年至 2008 年在纪念斯隆-凯特琳癌症中心接受局限性肺癌切除术的 962 例连续患者。分析纳入了有 CT 和 PET 扫描结果的患者。采用 25%的 C/T 比值(符合日本临床肿瘤学组 0201 标准)和 2.2(队列中位数)的 SUVmax 作为截止值。评估了累积复发率(CIR)。
共 181 例患者符合研究纳入标准。低 C/T 比值组(n=15)患者的 5 年复发率明显低于高 C/T 比值组(n=166)(5 年 CIR,0% vs. 33%;p=0.015),SUVmax 低值组(n=86)也明显低于 SUVmax 高值组(n=95)(5 年 CIR,18% vs. 40%;p=0.002)。此外,在高 C/T 比值组内,SUVmax 进一步分层了复发风险[5 年 CIR,22%(低值)vs. 40%(高值);p=0.018]。
随着 CT 筛查的广泛应用,预计小的肺 ADC 诊断数量将会增加,C/T 比值和 SUVmax 是广泛可用的标志物,可用于分层局限性切除后 cT1aN0M0 患者的复发风险。